trending Market Intelligence /marketintelligence/en/news-insights/trending/ukylep1a2y7kkz_cn5xfyq2 content esgSubNav
In This List

Knight Therapeutics secures Canadian rights to Ardelyx drug

Blog

Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share


Knight Therapeutics secures Canadian rights to Ardelyx drug

Ardelyx Inc. sold the Canadian rights to its medicine tenapanor to Knight Therapeutics Inc.

The medicine has been evaluated in a late-stage trial to treat irritable bowel syndrome with constipation and is being studied in a second phase 3 study for hyperphosphatemia, which causes an abnormally elevated level of phosphate in the blood.

Fremont, Calif.-based Ardelyx will receive C$25 million for the rights. The amount includes an undisclosed up-front payment from Montreal-based Knight Therapeutics.

In December 2017, Ardelyx sold the rights to develop and commercialize the drug in China to Shanghai Fosun Pharmaceutical (Group) Co. Ltd. for an up-front payment of $12 million.